Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection? - PubMed (original) (raw)

Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection?

Anne Buvé. F1000 Med Rep. 2010.

Abstract

Overwhelming evidence from observational epidemiological studies indicates that herpes simplex virus type 2 (HSV-2) infection enhances the risk of acquiring HIV infection. Studies of genital shedding of HIV have suggested that HSV-2 infection also increases the onward transmission of HIV-1 by HIV/HSV-2 co-infected patients. Several randomized controlled trials were initiated to assess the impact of HSV-2 suppressive therapy on the acquisition of HIV infection by HSV-2 infected men and women, and on the onward transmission of HIV by HSV-2/HIV co-infected men and women. In the past 2 years the results of these trials have been published. HSV-2 suppressive therapy was not found to have any effect on HIV acquisition nor on onward transmission of HIV. However, suppressive therapy with acyclovir was found to slow down disease progression in HIV/HSV-2 co-infected patients. The effect was rather modest and cost-effectiveness studies are needed to assess whether HSV-2 suppressive therapy has a place in the management of HIV-1 infected patients, especially in low and middle income countries.

PubMed Disclaimer

Similar articles

• A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
  Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, Robinson NJ, Bassett MT, Wilson D, Brown DW, Hayes RJ. Cowan FM, et al. Sex Transm Infect. 2008 Dec;84(7):548-53. doi: 10.1136/sti.2008.031153. Epub 2008 Aug 6. Sex Transm Infect. 2008. PMID: 18684855 Clinical Trial.
• Does suppressive antiviral therapy for herpes simplex virus prevent transmission in an HIV-positive population? A systematic review.
  Smith CR, Pogany L, Auguste U, Steben M, Lau T. Smith CR, et al. Can Commun Dis Rep. 2016 Feb 4;42(2):37-44. doi: 10.14745/ccdr.v42i02a03. eCollection 2016 Feb 4. Can Commun Dis Rep. 2016. PMID: 29770002 Free PMC article.
• The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic.
  Barton S, Celum C, Shacker TW. Barton S, et al. Herpes. 2005 Jun;12(1):15-22. Herpes. 2005. PMID: 16026640 Review.
• The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
  Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G. Vickerman P, et al. Sex Transm Dis. 2011 May;38(5):401-9. doi: 10.1097/OLQ.0b013e31820b8bc8. Sex Transm Dis. 2011. PMID: 21317689 Clinical Trial.
• Genital herpes simplex virus infections.
  Mertz GJ. Mertz GJ. Med Clin North Am. 1990 Nov;74(6):1433-54. doi: 10.1016/s0025-7125(16)30489-8. Med Clin North Am. 1990. PMID: 2246948 Review.

Cited by

• A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.
  Balzarini J, Andrei G, Balestra E, Huskens D, Vanpouille C, Introini A, Zicari S, Liekens S, Snoeck R, Holý A, Perno CF, Margolis L, Schols D. Balzarini J, et al. PLoS Pathog. 2013;9(7):e1003456. doi: 10.1371/journal.ppat.1003456. Epub 2013 Jul 25. PLoS Pathog. 2013. PMID: 23935482 Free PMC article.
• Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.
  Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, Cihlar T, Perno CF, Snoeck R, Margolis L, Balzarini J. Andrei G, et al. Cell Host Microbe. 2011 Oct 20;10(4):379-89. doi: 10.1016/j.chom.2011.08.015. Cell Host Microbe. 2011. PMID: 22018238 Free PMC article.
• Algal lectins as potential HIV microbicide candidates.
  Huskens D, Schols D. Huskens D, et al. Mar Drugs. 2012 Jul;10(7):1476-1497. doi: 10.3390/md10071476. Epub 2012 Jul 10. Mar Drugs. 2012. PMID: 22851920 Free PMC article. Review.

References

1. 1. UNAIDS AIDS Epidemic Update. 2009. UNAIDS/09.36E / JC1700E. Geneva: Joint United Nations Programme on HIV/AIDS. [ http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf]
2. 1. World Health Organization Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2009. Geneva: World Health Organization; 2009.
3. 1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3–17. doi: 10.1136/sti.75.1.3. - DOI - PMC - PubMed
4. 1. Korenromp EL, White RG, Orroth KK, Bakker R, Kamali A, Serwadda D, Gray RH, Grosskurth H, Habbema JD, Hayes RJ. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis. 2005;191(Suppl 1):S168–78. doi: 10.1086/425274. - DOI - PubMed
5. 1. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11(Suppl 1):24A–35A. - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • H1 Connect
  • PubMed Central

• Miscellaneous

  • NCI CPTAC Assay Portal